Related Experiment Video
Updated: Apr 22, 2026
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
7.5K
Rethinking our strategies to develop disease-modifying therapies for Parkinson's: Time for combination therapies?
Paloma Fernandez1,2, Rachel M Hughes1, Helen Matthews1
1Cure Parkinson's, London, UK.
Journal of Parkinson'S Disease
|April 21, 2026
Summary
Parkinson's disease (PD) lacks disease-modifying therapies (DMTs). This commentary proposes combination therapies targeting multiple etiological factors as a novel strategy for PD drug development.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Trials
Background:
- Significant progress in understanding Parkinson's disease (PD) pathogenesis has not yielded disease-modifying therapies (DMTs).
- Limited success in advancing PD drug candidates to late-stage clinical trials highlights therapeutic development challenges.
- Recent high-profile trial failures underscore the urgent need for novel therapeutic strategies.
Purpose of the Study:
- To propose an alternative strategy for identifying effective Parkinson's disease (PD) disease-modifying therapies (DMTs).
- To advocate for the investigation of rationally designed combination therapies in PD drug development.
Main Methods:
- This commentary proposes a strategic shift in PD therapeutic development.
- The strategy involves evaluating combination therapies designed to address multiple etiological factors of PD.
Main Results:
- The current approach to PD drug discovery has yielded limited success in identifying DMTs.
- A proposed alternative strategy focuses on combination therapies targeting multiple PD pathways.
Conclusions:
- Rationally designed combination therapies offer a promising alternative strategy for developing effective Parkinson's disease (PD) disease-modifying therapies (DMTs).
- Targeting multiple etiological factors simultaneously may overcome the limitations of single-target approaches in PD treatment.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:15Parkinson's Disease: Overview
2.1K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.1K
01:24Parkinson Disease l: Introduction
6
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
6
01:24Parkinson Disease ll: Pathophysiology
11
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
11
01:28Drug Therapy
436
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
436
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K